Suven Life Sciences share news, announcements and annual reports
NSE: SUVENBSE: 530239Healthcare ServicesSmall Cap
Suven Life Sciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Oct 2003 on NSE
Last close ₹258.85down ₹5.35 (2.03%)BSE ₹258.10
Share price at the NSE close on 30 Oct 2026. Previous close ₹264.20.
30 Oct: open ₹263.50, high ₹265.65, low ₹257.00
52-week range of traded prices to 30 Oct 2026
₹124.11Low, 24 Mar 2026₹403.35High, 1 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹7,314 Cr806th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −100.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −63.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,27,67850.0% delivered
Suven Life Sciences share news and announcements
803 announcements, routine notices left out, newest first. Page 15 of 17.
Jan 2010
12 Jan · Business
Press release dated January 12, 2010, titled " Suven Secures Two product patents in China and Russia". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2009
14 Dec · Business
Press release dated December 14, 2009, titled " Suven Secures two Product patents from Canadian Intellectual Property Office."A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2009
30 Nov · Business
Press release dated November 30, 2009, titled "Suven Life Sciences secures Three European Patents on NCEs". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2009
31 Oct · Business
Press release dated October 31, 2009, titled "Suven spends 29.78% of Revenue on R&D for the quarter ending Sep 09". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Oct · Board meeting
Meeting on 31 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”20 Oct · Business
Press release dated October 20, 2009, titled "Suven Life Sciences presenting Pre-clinical data of their NCEs at Society for Neuroscience Annual Meeting, SFN-2009 at Chicago, USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Oct · Business
Press release dated October 14, 2009, titled "Suven's Clinical Candidate SUVN-502 For Alzheimer's disease Secures product patents in several Key markets in the world". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2009
23 Sep · Meeting
Members in the Annual General Meeting held on September 22, 2009 have unanimously approved the following matters : 1) Adoption of Audited Annual Accounts for the year 2008-2009. 2) Declared dividend of 0.25 paise (25%) per equity share for the year 2008-09. 3) Re-appointed Dr K V Raghavan as Director retiring by rotation. 4) Re-appointed Karvy & Co, Chartered Accountants as Statutory Auditors of the Company until the conclusion of next Annual General Meeting. 5) Appointed Shri D G Prasad as Director of the Company, liable to retire by rotation. 6) Appointed Dr Martin Tolar as Director of the Company, liable to retire by rotation. 7) Approved issue of ADRs/ GDRs/FCCBs or other convertible debt instruments or convertible securities for a sum of not exceeding 50Mn USD and authorized the Board of Directors in this behalf subject to necessary approvals, consents, if any from the statutory authorities.15 Sep · Business
Press release dated September 14, 2009, titled "Suven Life Sciences secures Two US Patents on NCEs". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Sep · Board meeting
To consider inter alia and approve Cost Accounts of the Company for the year 2008-09.7 Sep · News Release
News release dated September 07, 2009, titled "Suven achieves 1st Milestone payment in Drug Discovery collaboration". A copy of the news release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2009
25 Aug · Updates
Vide its letter dated August 24, 2009 that "Today, our Chairman & CEO, Shri Venkat Jasti held discussions with media about fund raising programmes of our company for the purpose of meeting clinical development expenditure for SUVN-502 and for creation of dedicated Drug Discovery Centre for which our Company is approaching the shareholders for their approval in the ensuing Annual General Meeting". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Aug · Meeting
Company has announced the Book Closure dates for the Register of members and Share Transfer from September 16, 2009 to September 18, 2009 for the purpose of Annual General Meeting to be held on September 22, 2009 and Dividend Declaration.
Jul 2009
29 Jul · Raising of funds
Board of Directors in its meeting held on July 28, 2009 considered and approved to raise funds to the tune of 50 Million USD or its equivalent of any other Foreign/ Indian currencies through issue of Equity Shares / GDRs / ADRs / FCCBs and /or such other securities either by way of international offerings and /or domestics offerings for purpose of meeting its R&D and clinical development expenditure and for creation of dedicated Drug Discovery Centre and / or for meeting company's on going expansion and upgradation plans, subject to necessary consents / approvals.28 Jul · Business
Press release dated July 28, 2009, titled "Suven's profit up by 37%, Spends 22% of Revenue on R&D". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Jul · Dividend
Board of Directors in its meeting held on July 28, 2009, recommended Dividend Re 0.25 paise per equity share of face value of Re 1/- each (25%) for the financial year ended March 31, 2009, subject to the approval of Members in ensuing Annual General Meeting. Further the Dr. Martin Tolar has joined the Board of Directors as Additional Director W.e.f. July 28, 2009. Further the Brief Financial as required to be furnished under clause 20 shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Jul · Business
Press release dated July 27, 2009, titled "Suven Presented Positive Phase-I clinical data of SUVN-502 for Alzheimer's disease at ICAD 2009, Vienna, Austria". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Jul · Board meeting
To consider, inter alia, and take on record the following matters: (1) To consider and approve the Audited Annual Accounts for the year ended March 31, 2009. (2) To recommend dividend for the financial year ended March 31, 2009, if any (3) To announce Book Closure for the purpose of AGM . (4) To consider and take on record the Un-audited Financial Results for the First Quarter ended June 30, 2009.
May 2009
6 May · Business
Press release dated May 06, 2009, titled "Suven's Unit - I Receives US FDA Acceptance". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2009
29 Apr · Business
Press release dated April 29, 2009, titled "Suven's revenue up by 19%, Spends 22% of Revenue on R&D". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Apr · Board meeting
To consider, inter alia, and take on record the Un-audited Financial Results for the Fourth Quarter ended March 31, 2009.9 Apr · Business
Press release dated April 09, 2009, titled "Suven completes Phase I Clinical Trials Multiple Ascending Dose of SUVN-502 in Switzerland". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2009
19 Jan · Management
Shri D G Prasad is appointed as additional director by the Board of Directors in its meeting held on January 19, 2009.19 Jan · Business
Press release dated January 19, 2009, titled "Suven's revenue up by 21%, Spends 24% of Revenue on R&D". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Jan · Management
Shri T R Prasad, Director, has resigned from the Board of the company w.e.f. January 13, 2009.13 Jan · Business
Press release dated January 13, 2009, titled ""Suven Particiapation at Biotech Showcase 2009" SanFrancisco, USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Jan · Board meeting
Meeting on 19 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Nov 2008
18 Nov · Business
Press release dated November 18, 2008, titled "Suven Life Sciences presenting Biology data of their NCE's at Society for Neuroscience Annual Meeting, SFN-2008 at Washington DC, USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Nov · News Release
News release dated November 18, 2008, titled "Suven participation at Bio-Europe 2008". A copy of the news release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Nov · Business
Press release dated November 11, 2008, titled "Suven Presentation at Rodman & Renshaw 10th Annual Healthcare Conference at New York being held from 10-12 November 2008". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Nov · Allotment of Equity Shares
The Compensation committee of Board of Directors of the company allotted 164,200 equity shares through circular resolution on 4th November, 2008 under stock option plan of the company. Further consequent to the above allotment, paid up share capital of the company has gone up from 115710200 equity shares of Re 1/- each aggregating to Rs. 115710200 to 115874400 equity shares of Re 1/- each aggregating Rs 115874400/-
Oct 2008
31 Oct · News Release
News release dated October 31, 2008, titled "Suven's net up by 50%, Spends 17% of Revenue on R&D". A copy of the news release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.31 Oct · Business
Press release dated October 31, 2008, titled "Suven's net up by 50%, Spends 17% of Revenue on R&D". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Oct · Management
We are deeply saddened by the news of sudden demise of our Company's beloved Chairman, Shri Bodhishwar Rai on 16th October 2008. He is ceased to be Director of the Company from the said date21 Oct · Board meeting
Meeting on 31 Oct 2008: “Unaudited financial results for qtr ended September 30, 2008”13 Oct · Business
Press release dated October 13, 2008, titled "SUVN-502 data being presented at 16th BioPartnering in London". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2008
29 Sep · Business
Press release dated September 29, 2008, titled "Suven completed Phase-I Clinical Trials Single Ascending Dose of SUVN-502 in Switzerland". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Sep · Business
Press release dated September 25, 2008, titled " DCGI nod to conduct Phase-I Clinical Trials of SUVN-502 for Alzheimer's disease". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Sep · Board meeting
Board of Directors at their meeting held on September 18, 2008, have approved the Cost Accounts for the year 2007-08.18 Sep · Meeting
Outcome of Annual General Meeting held on September 18, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Sep · Board meeting
To consider and approve Cost Accounts of the Company for the year 2007-08.
Aug 2008
12 Aug · Business
Press release dated August 12, 2008, titled "Asian Clinical Trials (ACT), the CRO division of Suven commences clinical research services from Raleigh, North Carolina, USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Aug · Meeting
Company has announced the Book Closure dates for the Register of members and Share Transfer from September 13, 2008 to September 15, 2008 for the purpose of Annual General Meeting to held on September 18, 2008 and dividend declaration.4 Aug · Business
Press release dated August 04, 2008, titled "Suven Life Sciences Presents Positive Preclinical Data for SUVN-502 at Alzheimer's conference, Chicago and Drug Discovery conference, Boston". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2008
25 Jul · Business
Press release dated July 25, 2008, titled "Revenue growth for quarter at 11.43%, Commences Phase 1 clinical trial of SUVN-502 in Switzerland for Alzheimer's Disease". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Jul · Updates
Brief financials as required to be furnished under clause 20. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Jul · Dividend
Board of Directors in its meeting held on July 25, 2008 has recommended Dividend @ 25% of face value of Re 1/- each (Re 0.25 paise per share) for the financial year ended March 31, 2008, subject to the approval of Members in ensuing Annual General Meeting.16 Jul · Board meeting
To consider, inter alia, and take on record the following matters: (1) To consider and approve the Audited Annual Accounts for the year ended March 31, 2008. (2) To recommend dividend for the financial year ended March 31, 2008, subject to approval of Shareholders at the ensuing AGM. (3) To announce Book Closure for the purpose of AGM and distribution of Dividend. (4) To consider and take on record the Un-audited Financial Results for the First Quarter ended June 30, 2008.7 Jul · Business
Press release dated July 07, 2008, titled "Suven Life Sciences Clinical candidate SUVN-502 being presented at International Conference on Alzheimer's Disease, ICAD-2008 at Chicago, USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2008
18 Jun · Business
Press release dated June 18, 2008, titled "Suven Life Sciences Initiates Phase I Clinical Trials in Europe of SUVN-502 for Alzheimer's disease". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.